Aliskiren targets multiple systems to alleviate cancer cachexia

Wang,Chaoyi; Guo,Dunwei; Wang,Qiang; You,Song; Qiao,Zhongpeng; Liu,Yong; Dai,Hang; Tang,Hua

doi:10.3892/or.2016.5118

Aliskiren targets multiple systems to alleviate cancer cachexia

Authors:
- Chaoyi Wang
- Dunwei Guo
- Qiang Wang
- Song You
- Zhongpeng Qiao
- Yong Liu
- Hang Dai
- Hua Tang
View Affiliations

Affiliations: Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China
Published online on: September 21, 2016 https://doi.org/10.3892/or.2016.5118
Pages: 3014-3022

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To examine the effects of aliskiren, a small-molecule renin inhibitor, on cancer cachexia and to explore the underlying mechanisms. A cancer cachexia model was established by subcutaneously injecting C26 mouse colon carcinoma cells into isogenic BALB/c mice. Aliskiren was administered intragastrically [10 mg/kg body weight (BW)] on day 5 (as a preventive strategy, AP group) or on day 12 (as a therapeutic strategy, AT group) after C26 injection. Mice that received no C26 injection (healthy controls, HC group) or only C26 injection but not aliskiren (cancer, CA group) were used as controls. BW, tumor growth, whole body functions, and survival were monitored daily in half of the mice in each group, whereas serum, tumors, and gastrocnemius muscles were harvested from the other mice after sacrifice on day 20 for further analysis. Aliskiren significantly alleviated multiple cachexia‑associated symptoms, including BW loss, tumor burden, muscle wasting, muscular dysfunction, and shortened survival. On the molecular level, aliskiren antagonized cachexia‑induced activation of the renin‑angiotensin system (RAS), systematic and muscular inflammation, oxidative stress, and autophagy‑lysosome as well as ubiquitin‑proteasome stimulation. In addition, early administration of aliskiren before cachexia development (AP group) resulted in more robust effects in alleviating cachexia or targeting underlying mechanisms than administration after cachexia development (AT group). Aliskiren exhibited potent anti‑cachexia activities. These activities were achieved through the targeting of at least four mechanisms underlying cachexia development: RAS activation, increase in systematic inflammation, upregulation of oxidative stress, and stimulation of autophagy-lysosome pathway (ALP) and ubiquitin-proteasome pathway (UPP).

View Figures

View References

1	Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, et al: Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 12:489–495. 2011. View Article : Google Scholar : PubMed/NCBI
2	Tan BH and Fearon KC: Cachexia: Prevalence and impact in medicine. Curr Opin Clin Nutr Metab Care. 11:400–407. 2008. View Article : Google Scholar : PubMed/NCBI
3	Tisdale MJ: Mechanisms of cancer cachexia. Physiol Rev. 89:381–410. 2009. View Article : Google Scholar : PubMed/NCBI
4	Russell ST, Sanders PM and Tisdale MJ: Angiotensin II directly inhibits protein synthesis in murine myotubes. Cancer Lett. 231:290–294. 2006. View Article : Google Scholar : PubMed/NCBI
5	Sanders PM, Russell ST and Tisdale MJ: Angiotensin II directly induces muscle protein catabolism through the ubiquitin-proteasome proteolytic pathway and may play a role in cancer cachexia. Br J Cancer. 93:425–434. 2005. View Article : Google Scholar : PubMed/NCBI
6	Ruiz-Ortega M, Lorenzo O, Suzuki Y, Rupérez M and Egido J: Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens. 10:321–329. 2001. View Article : Google Scholar : PubMed/NCBI
7	Zhang L, Du J, Hu Z, Han G, Delafontaine P, Garcia G and Mitch WE: IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting. J Am Soc Nephrol. 20:604–612. 2009. View Article : Google Scholar : PubMed/NCBI
8	Russell ST, Eley H and Tisdale MJ: Role of reactive oxygen species in protein degradation in murine myotubes induced by proteolysis-inducing factor and angiotensin II. Cell Signal. 19:1797–1806. 2007. View Article : Google Scholar : PubMed/NCBI
9	Sukhanov S, Semprun-Prieto L, Yoshida T, Michael Tabony A, Higashi Y, Galvez S and Delafontaine P: Angiotensin II, oxidative stress and skeletal muscle wasting. Am J Med Sci. 342:143–147. 2011. View Article : Google Scholar : PubMed/NCBI
10	Dalla Libera L, Ravara B, Angelini A, Rossini K, Sandri M, Thiene G, Battista Ambrosio G and Vescovo G: Beneficial effects on skeletal muscle of the angiotensin II type 1 receptor blocker irbesartan in experimental heart failure. Circulation. 103:2195–2200. 2001. View Article : Google Scholar : PubMed/NCBI
11	Neo JH, Ager EI, Angus PW, Zhu J, Herath CB and Christophi C: Changes in the renin angiotensin system during the development of colorectal cancer liver metastases. BMC Cancer. 10:1342010. View Article : Google Scholar : PubMed/NCBI
12	Sun G, Haginoya K, Dai H, Chiba Y, Uematsu M, Hino-Fukuyo N, Onuma A, Iinuma K and Tsuchiya S: Intramuscular renin-angio-tensin system is activated in human muscular dystrophy. J Neurol Sci. 280:40–48. 2009. View Article : Google Scholar : PubMed/NCBI
13	Wang XH and Mitch WE: Mechanisms of muscle wasting in chronic kidney disease. Nat Rev Nephrol. 10:504–516. 2014. View Article : Google Scholar : PubMed/NCBI
14	Murphy KT, Chee A, Trieu J, Naim T and Lynch GS: Inhibition of the renin-angiotensin system improves physiological outcomes in mice with mild or severe cancer cachexia. Int J Cancer. 133:1234–1246. 2013. View Article : Google Scholar : PubMed/NCBI
15	Wang Q, Li C, Peng X, Kang Q, Deng D, Zhang L, Zheng Y, Wang C, Qiao Z, Guo D, et al: Combined treatment of carfilzomib and z-VAD-fmk inhibits skeletal proteolysis and apoptosis and ameliorates cancer cachexia. Med Oncol. 32:1002015. View Article : Google Scholar : PubMed/NCBI
16	Acharyya S and Guttridge DC: Cancer cachexia signaling pathways continue to emerge yet much still points to the proteasome. Clin Cancer Res. 13:1356–1361. 2007. View Article : Google Scholar : PubMed/NCBI
17	Penna F, Baccino FM and Costelli P: Coming back: Autophagy in cachexia. Curr Opin Clin Nutr Metab Care. 17:241–246. 2014. View Article : Google Scholar : PubMed/NCBI
18	Del Fiorentino A, Cianchetti S, Celi A and Pedrinelli R: Aliskiren, a renin inhibitor, downregulates TNF-α-induced tissue factor expression in HUVECS. J Renin Angiotensin Aldosterone Syst. 11:243–247. 2010. View Article : Google Scholar : PubMed/NCBI
19	Patel RB, Prajapati KD, Sonara BM, Sharma MM, Patel HM, Pawar VD and Jain MR: Ameliorative potential of aliskiren in experimental colitis in mice. Eur J Pharmacol. 737:70–76. 2014. View Article : Google Scholar : PubMed/NCBI
20	Schmerbach K, Pfab T, Zhao Y, Culman J, Mueller S, Villringer A, Muller DN, Hocher B, Unger T and Thoene-Reineke C: Effects of aliskiren on stroke in rats expressing human renin and angiotensinogen genes. PLoS One. 5:e150522010. View Article : Google Scholar : PubMed/NCBI
21	De Luca A, Pierno S, Liantonio A, Cetrone M, Camerino C, Fraysse B, Mirabella M, Servidei S, Rüegg UT and Conte Camerino D: Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1. J Pharmacol Exp Ther. 304:453–463. 2003. View Article : Google Scholar
22	Ham DJ, Murphy KT, Chee A, Lynch GS and Koopman R: Glycine administration attenuates skeletal muscle wasting in a mouse model of cancer cachexia. Clin Nutr. 33:448–458. 2014. View Article : Google Scholar
23	Murphy KT, Chee A, Trieu J, Naim T and Lynch GS: Importance of functional and metabolic impairments in the characterization of the C-26 murine model of cancer cachexia. Dis Model Mech. 5:533–545. 2012. View Article : Google Scholar : PubMed/NCBI
24	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
25	Tanaka Y, Eda H, Tanaka T, Udagawa T, Ishikawa T, Horii I, Ishitsuka H, Kataoka T and Taguchi T: Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice. Cancer Res. 50:2290–2295. 1990.PubMed/NCBI
26	Guo CB, Zhang W, Ma DQ, Zhang KH and Huang JQ: Hand grip strength: An indicator of nutritional state and the mix of postoperative complications in patients with oral and maxillofacial cancers. Br J Oral Maxillofac Surg. 34:325–327. 1996. View Article : Google Scholar : PubMed/NCBI
27	Carson JA and Baltgalvis KA: Interleukin 6 as a key regulator of muscle mass during cachexia. Exerc Sport Sci Rev. 38:168–176. 2010. View Article : Google Scholar : PubMed/NCBI
28	Deans C and Wigmore SJ: Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care. 8:265–269. 2005. View Article : Google Scholar : PubMed/NCBI
29	Tsoli M and Robertson G: Cancer cachexia: Malignant inflammation, tumorkines, and metabolic mayhem. Trends Endocrinol Metab. 24:174–183. 2013. View Article : Google Scholar
30	Vaughan VC, Martin P and Lewandowski PA: Cancer cachexia: Impact, mechanisms and emerging treatments. J Cachexia Sarcopenia Muscle. 4:95–109. 2013. View Article : Google Scholar :
31	Thomas CM, Yong QC, Seqqat R, Chandel N, Feldman DL, Baker KM and Kumar R: Direct renin inhibition prevents cardiac dysfunction in a diabetic mouse model: Comparison with an angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor. Clin Sci (Lond). 124:529–541. 2013. View Article : Google Scholar
32	Penna F, Costamagna D, Pin F, Camperi A, Fanzani A, Chiarpotto EM, Cavallini G, Bonelli G, Baccino FM and Costelli P: Autophagic degradation contributes to muscle wasting in cancer cachexia. Am J Pathol. 182:1367–1378. 2013. View Article : Google Scholar : PubMed/NCBI
33	Tardif N, Klaude M, Lundell L, Thorell A and Rooyackers O: Autophagic-lysosomal pathway is the main proteolytic system modified in the skeletal muscle of esophageal cancer patients. Am J Clin Nutr. 98:1485–1492. 2013. View Article : Google Scholar : PubMed/NCBI
34	McClung JM, Judge AR, Powers SK and Yan Z: p38 MAPK links oxidative stress to autophagy-related gene expression in cachectic muscle wasting. Am J Physiol Cell Physiol. 298:C542–C549. 2010. View Article : Google Scholar :
35	Rahman M, Mofarrahi M, Kristof AS, Nkengfac B, Harel S and Hussain SN: Reactive oxygen species regulation of autophagy in skeletal muscles. Antioxid Redox Signal. 20:443–459. 2014. View Article : Google Scholar
36	Weng LQ, Zhang WB, Ye Y, Yin PP, Yuan J, Wang XX, Kang L, Jiang SS, You JY, Wu J, et al: Aliskiren ameliorates pressure overload-induced heart hypertrophy and fibrosis in mice. Acta Pharmacol Sin. 35:1005–1014. 2014. View Article : Google Scholar : PubMed/NCBI
37	Zhang W, Zhao G, Hu X, Wang M, Li H, Ye Y, Du Q, Yao J, Bao Z, Hong W, et al: Aliskiren-attenuated myocardium apoptosis via regulation of autophagy and connexin-43 in aged spontaneously hypertensive rats. J Cell Mol Med. 18:1247–1256. 2014. View Article : Google Scholar : PubMed/NCBI
38	Burckart K, Beca S, Urban RJ and Sheffield-Moore M: Pathogenesis of muscle wasting in cancer cachexia: Targeted anabolic and anticatabolic therapies. Curr Opin Clin Nutr Metab Care. 13:410–416. 2010. View Article : Google Scholar : PubMed/NCBI
39	Yuan L, Han J, Meng Q, Xi Q, Zhuang Q, Jiang Y, Han Y, Zhang B, Fang J and Wu G: Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: An in vitro and in vivo study. Oncol Rep. 33:2261–2268. 2015.PubMed/NCBI